Eledon Pharmaceuticals, Inc. (ELDN) is an innovative biopharmaceutical company founded with the vision of treating or preventing a variety of severe autoimmune, inflammatory, and metabolic disorders. Headquartered in Irvine, California, Eledon Pharma, which was formerly known as Novus Therapeutics, focuses on developing innovative medicines designed to restore functions of damaged or missing cells, known as cellular reprogramming.
The company's transformational technology has the potential to stimulate the production of a broad range of cell types for systemic in vivo administration or direct organ-targeting applications. This technology allows treatments to repair or replace damaged or deficient cells, potentially offering a revolutionary approach to long-standing health issues.
Eledon's leading experimental drug candidate is AT-1501, aimed at halting the progression of neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS) and preventing organ transplant rejection. Interestingly, AT-1501 is an antibody that targets and blocks a distinct protein called CD40 Ligand (CD40L) - a co-stimulatory protein required for T cell activation. By targeting CD40L, AT-1501 prevents immune-mediated attacks, making it a potentially life-changing treatment for patients suffering from life-threatening immune system disorders.
The company's pioneering medical offerings are testament to its commitment in breaking new grounds in the biopharmaceutical industry, underlining Eledon’s emphasis on using science and technology as weapons to fight devastating diseases. Eledon is led by a team of industry veterans who bring a wealth of drug development and commercialization experience to the company.
Since its establishment, Eledon has shown impressive strides towards making its vision a reality. However, as with any biopharmaceutical firm, the road to breakthrough products is fraught with technical obstacles, regulatory complexities, and clinical trial uncertainties. Still, Eledon is passionately accepting these challenges and is continually striving to make significant advancements in the world of medical science.
In conclusion, Eledon Pharmaceuticals, Inc. (ELDN) is making its presence felt with its pioneering approach to finding solutions to some of healthcare's most complex challenges. Its philosophy of transformative cellular treatments, entrepreneurship, and its development of the experimental drug candidate AT-1501 are confirmation of Eledon's commitment to bringing innovative and more effective therapies to patients worldwide.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Eledon Pharmaceuticals Inc. saw its shares rise 13% after presenting updated long-term data from its Phase 2 trial of tegoprubart, a drug for preventing organ transplant rejection. The data showed improved kidney function and fewer rejections among treated patients compared to standard care. The company plans to initiate a Phase 3 trial in Q4 of this year, following the FDA's fast track designation for tegoprubart.
Eledon Pharmaceuticals, Inc. (ELDN) presented a slideshow at the International Congress of The Transplantation Society 2026. The presentation materials were made public by the company in conjunction with this event. SA Transcripts provided this update for investors.
Eledon Pharmaceuticals (ELDN) has submitted an Investigational New Drug (IND) application to the US FDA for tegoprubart. The company is developing this immune-modulating therapy for islet cell transplantation and has also begun enrolling patients in multiple transplant programs. Tegoprubart is an anti-CD40L antibody designed to improve safety and offer pharmacokinetic, pharmacodynamic, and dosing advantages.